Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ABP688 | Experimental | Elderly MDD patients and demography matched healthy volunteer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABP688 | Drug | Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Binding of [11C] ABP688 to mGlu5 receptors | Binding of [11C]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes | Day 1 |
| Blood levels of [11C] ABP688 | Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of [11C] ABP688. Specific times are recorded at the clinical site. | Day 1, up to 60 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in [11C]ABP688 binding to mGlu5 receptors | Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients. | Day 1 |
Not provided
Inclusion Criteria:
At screening:
Specific to Major depression disorder (MDD)
Patients had to show following level of symptomatology:
Exclusion Criteria:
Specific criteria for healthy volunteers:
- Presence and/or history of clinically significant major neurological or psychiatric disorder
Specific criteria for MDD patients:
Criteria for both:
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | New York | New York | United States | |||
| Novartis Investigative Site |
Not provided
| Label | URL |
|---|---|
| Results for CABP688A2102 can be found on the Novartis Clinical Trial Results Website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C510950 | 3-(6-methylpyridin-2-ylethynyl)cyclohex-2-enone-O-methyloxime |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pittsburgh |
| Pennsylvania |
| United States |